Genetic Testing of Cerebrospinal Fluid to Diagnose and Monitor Glioblastoma

Evaluating the Role of Cerebrospinal Fluid (CSF) Cell-free DNA (cfDNA) as a Prognostic Biomarker in Glioblastoma

The goal of this study is to determine the utility of cerebrospinal fluid (CSF) cell-free DNA (cfDNA) as a prognostic biomarker in glioblastoma (GBM).

Inclusion Criteria:

Cohort A

• Participants must be able to understand and be willing to sign a written informed consent document
• Age ≥ 18 years
• MRI with contrast-enhancing lesion concerning for high-grade glioma in absence of known systemic malignancy
• Clinical consensus of presumed diagnosis of high grade glioma between (1) neuroradiology (2) neurosurgery; and (3) principal investigator
• No prior tumor directed therapy
• Planned radiation therapy for glioblastoma
• Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• Patients must be willing to consent to MSK IRB#12-245

Cohort B

• Participants must be able to understand and be willing to sign a written informed consent document
• Age ≥ 18 years
• Histologic confirmed glioblastoma (WHO grade IV), IDH wild type per IHC
• No prior tumor-directed therapies except surgical resection or biopsy
• Patients who have gliadel wafers placed during upfront surgery are excluded
• Planned radiation therapy for glioblastoma
• Patients must be willing and able to tolerate MRI scans and/or CT scans w/ contrast
• Patients must be willing to consent to MSK IRB#12-245

Exclusion Criteria:

Cohorts A and B

• Any case for which there is a medical contraindication or safety concern regarding a lumbar puncture under standard medical guidelines at MSK
• Refusal to undergo serial lumbar punctures